Vir Biotechnology, Inc. NASDAQ:VIR

Vir Biotechnology stock price today

$4.35
-3.12
-41.77%
Financial Health
0
1
2
3
4
5
6
7
8
9

Vir Biotechnology stock price monthly change

-20.28%
month

Vir Biotechnology stock price quarterly change

-20.28%
quarter

Vir Biotechnology stock price yearly change

-26.91%
year

Vir Biotechnology key metrics

Market Cap
1.02B
Enterprise value
2.39B
P/E
5.98
EV/Sales
1.48
EV/EBITDA
3.10
Price/Sales
1.92
Price/Book
1.50
PEG ratio
-0.48
EPS
-4.01
Revenue
56.34M
EBITDA
-554.72M
Income
-539.43M
Revenue Q/Q
20.68%
Revenue Y/Y
-85.81%
Profit margin
31.92%
Oper. margin
51.56%
Gross margin
90.94%
EBIT margin
51.56%
EBITDA margin
-984.55%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Vir Biotechnology stock price history

Vir Biotechnology stock forecast

Vir Biotechnology financial statements

Vir Biotechnology, Inc. (NASDAQ:VIR): Profit margin
Jun 2023 -12.72M -194.77M 1531.01%
Sep 2023 -4.09M -163.41M 3987.63%
Dec 2023 16.78M -115.97M -690.85%
Mar 2024 56.37M -65.27M -115.79%
Vir Biotechnology, Inc. (NASDAQ:VIR): Analyst Estimates
Mar 2024 56.37M -65.27M -115.79%
Sep 2025 18.4M -150.76M -819.36%
Oct 2025 18.4M -129.86M -705.81%
Dec 2025 18.4M -78.46M -426.43%
  • Analysts Price target

  • Financials & Ratios estimates

Vir Biotechnology, Inc. (NASDAQ:VIR): Debt to assets
Jun 2023 2243874000 433.66M 19.33%
Sep 2023 2044895000 369.81M 18.08%
Dec 2023 1960090000 369.85M 18.87%
Mar 2024 1793969000 246.61M 13.75%
Vir Biotechnology, Inc. (NASDAQ:VIR): Cash Flow
Jun 2023 -389.24M 230.31M 3.17M
Sep 2023 -155.82M -58.95M 277K
Dec 2023 -107.92M -104.81M 1.68M
Mar 2024 -109.39M 28.42M 152K

Vir Biotechnology alternative data

Vir Biotechnology, Inc. (NASDAQ:VIR): Employee count
Aug 2023 576
Sep 2023 576
Oct 2023 576
Nov 2023 576
Dec 2023 576
Jan 2024 576
Feb 2024 576
Mar 2024 587
Apr 2024 587
May 2024 587
Jun 2024 587
Jul 2024 587

Vir Biotechnology other data

57.90% -5.69%
of VIR is owned by hedge funds
76.69M -8.85M
shares is hold by hedge funds

Vir Biotechnology, Inc. (NASDAQ:VIR): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 85685
Mar 2024 0 6008
Apr 2024 0 75706
Jun 2024 0 4000
Sep 2024 0 12190
Nov 2024 0 8147
Dec 2024 0 76
Transaction Date Insider Security Shares Price per share Total value Source
Sale
DE VERNEUIL VANINA officer: EVP and General Counsel
Common Stock 76 $8.22 $625
Sale
DE VERNEUIL VANINA officer: EVP and General Counsel
Common Stock 4,397 $10.11 $44,454
Sale
DE VERNEUIL VANINA officer: EVP and General Counsel
Common Stock 2,347 $9.47 $22,226
Sale
DE VERNEUIL VANINA officer: EVP and General Counsel
Common Stock 1,403 $7.2 $10,107
Sale
NAPOLITANO JANET director
Common Stock 12,190 $7.8 $95,033
Sale
RAMASASTRY SAIRA director
Common Stock 4,000 $10.95 $43,788
Sale
DE BACKER MARIANNE director, officer: Chief Execut..
Common Stock 72,995 $9.46 $690,387
Sale
HANLY ANN M. officer: EVP & Chief Technology..
Common Stock 2,711 $10.05 $27,251
Sale
LEE SUNG officer: EVP & Chief Financial ..
Common Stock 6,008 $9.89 $59,407
Sale
SCANGOS GEORGE A director Common Stock 17,722 $11.65 $206,514
Patent
Application
Filling date: 10 Nov 2021 Issue date: 28 Apr 2022
Application
Filling date: 19 Dec 2019 Issue date: 24 Feb 2022
Application
Filling date: 20 Sep 2019 Issue date: 3 Feb 2022
Application
Filling date: 23 Jul 2021 Issue date: 2 Dec 2021
Grant
Filling date: 25 Feb 2021 Issue date: 9 Nov 2021
Application
Filling date: 25 Feb 2021 Issue date: 26 Aug 2021
Application
Filling date: 31 Aug 2020 Issue date: 18 Feb 2021
Application
Filling date: 31 Aug 2020 Issue date: 18 Feb 2021
Grant
Filling date: 5 Oct 2015 Issue date: 19 Jan 2021
Wednesday, 18 December 2024
businesswire.com
Friday, 13 December 2024
seekingalpha.com
Thursday, 12 December 2024
businesswire.com
Tuesday, 26 November 2024
businesswire.com
Monday, 25 November 2024
businesswire.com
Monday, 18 November 2024
businesswire.com
businesswire.com
Friday, 15 November 2024
businesswire.com
Tuesday, 5 November 2024
seekingalpha.com
Thursday, 31 October 2024
seekingalpha.com
zacks.com
Thursday, 17 October 2024
businesswire.com
Thursday, 3 October 2024
businesswire.com
Tuesday, 6 August 2024
zacks.com
247wallst.com
Thursday, 1 August 2024
seekingalpha.com
zacks.com
businesswire.com
Thursday, 18 July 2024
businesswire.com
Wednesday, 17 July 2024
seekingalpha.com
Thursday, 4 July 2024
investorplace.com
Wednesday, 26 June 2024
businesswire.com
Thursday, 6 June 2024
zacks.com
Wednesday, 5 June 2024
businesswire.com
Wednesday, 29 May 2024
businesswire.com
businesswire.com
Thursday, 23 May 2024
businesswire.com
Wednesday, 22 May 2024
businesswire.com
businesswire.com
Tuesday, 21 May 2024
businesswire.com
  • What's the price of Vir Biotechnology stock today?

    One share of Vir Biotechnology stock can currently be purchased for approximately $4.35.

  • When is Vir Biotechnology's next earnings date?

    Unfortunately, Vir Biotechnology's (VIR) next earnings date is currently unknown.

  • Does Vir Biotechnology pay dividends?

    No, Vir Biotechnology does not pay dividends.

  • How much money does Vir Biotechnology make?

    Vir Biotechnology has a market capitalization of 1.02B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 94.55% to 86.18M US dollars.

  • What is Vir Biotechnology's stock symbol?

    Vir Biotechnology, Inc. is traded on the NASDAQ under the ticker symbol "VIR".

  • What is Vir Biotechnology's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Vir Biotechnology?

    Shares of Vir Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Vir Biotechnology's key executives?

    Vir Biotechnology's management team includes the following people:

    • Dr. Herbert W. Virgin IV Executive Vice President of Research & Chief Scientific Officer(age: 69, pay: $1,110,000)
    • Dr. George A. Scangos Pres, Chief Executive Officer & Director(age: 77, pay: $994,880)
    • Mr. Steven J. Rice Chief Admin. Officer(age: 65, pay: $698,620)
    • Mr. Howard Horn Chief Financial Officer & Sec.(age: 47, pay: $681,830)
  • How many employees does Vir Biotechnology have?

    As Jul 2024, Vir Biotechnology employs 587 workers.

  • When Vir Biotechnology went public?

    Vir Biotechnology, Inc. is publicly traded company for more then 5 years since IPO on 11 Oct 2019.

  • What is Vir Biotechnology's official website?

    The official website for Vir Biotechnology is vir.bio.

  • Where are Vir Biotechnology's headquarters?

    Vir Biotechnology is headquartered at 499 Illinois Street, San Francisco, CA.

  • How can i contact Vir Biotechnology?

    Vir Biotechnology's mailing address is 499 Illinois Street, San Francisco, CA and company can be reached via phone at +41 59064324.

Vir Biotechnology company profile:

Vir Biotechnology, Inc.

vir.bio
Exchange:

NASDAQ

Full time employees:

587

Industry:

Biotechnology

Sector:

Healthcare

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

499 Illinois Street
San Francisco, CA 94158

CIK: 0001706431
ISIN: US92764N1028
CUSIP: 92764N102